NCT07934745
Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: From enrolment until first documented disease progression, death, subsequent anti-cancer therapy, or loss to follow-up,assessed up to 24 months. Responses require confirmation ≥4 weeks after first documentation.
Secondary (3)
3-year Overall survival rate
3-year Disease-Free Survival (DFS) Rate
Adverse Events (AEs)
Arms and interventions
treatmentExperimental
Radiotherapy is delivered to recurrent or metastatic lesions. Thereafter, the PD-1 inhibitor putelimab in combination with the EGFR-targeted ADC vibostolimab is administered once every 3 weeks until disease progression or intolerable toxicity.
Drugs: putelimab combined with vibostolimab